Menlo Park, CA, November 13, 2017 – Kedalion Therapeutics, Inc., a clinical-stage company focused on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream™ platform, today announced the appointment of Peter Noymer, Ph.D., as President and Chief Executive Officer.
“Kedalion’s AcuStream platform is poised to revolutionize the way patients receive their ophthalmic medications. After extensive search, we are extremely pleased to bring Peter on board to lead the company,” said Mark Blumenkranz, M.D., M.M.S., Executive Chairman, Kedalion. “With more than two decades of experience in research, development and commercialization of pharmaceutical products with novel delivery systems, we are confident in Peter’s ability to advance this platform and accelerate the growth of company.”
“I am excited by the opportunity to lead this company and to join the team that Dr. Blumenkranz has built so far,” said Peter Noymer, Ph.D., President and Chief Executive Officer, Kedalion. “The AcuStream platform is innovative and well positioned to transform therapeutic outcomes for patients who struggle with standard eye drops every single day.”
Prior to joining Kedalion, Dr. Noymer served as Chief Operating Officer at SteadyMed Ltd., a specialty pharmaceutical company focused on treating unmet needs in pulmonary arterial hypertension with its proprietary PatchPumpTM technology. Earlier, he was Vice President of Product R&D at Alexza Pharmaceuticals, which obtained U.S and E.U. regulatory approvals for Adasuve®, the first inhalable treatment for acute agitation in patients with respiratory conditions. He also served in various management positions at Aradigm Corporation (NASDAQ: ARDM) earlier in his career. Dr. Noymer earned a B.S.E. degree with honors in engineering from Princeton University, and S.M. and Ph.D. degrees in engineering from the Massachusetts Institute of Technology.
About Kedalion Therapeutics
Kedalion Therapeutics is a venture-backed, clinical-stage biotechnology company whose mission is to bring to market transformative topical ophthalmic therapies for new and existing indications. Kedalion’s proprietary AcuStream platform technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable effect with up to an 80% reduction in dose compared to standard eye drops. Kedalion is based in Menlo Park, CA. For more information, visit www.kedalionthera.wpengine.com.